Loading
SP140 (Nuclear body protein SP140) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma and Mantle cell lymphoma.
Component of the nuclear body, also known as nuclear domain 10, PML oncogenic domain, and KR body. May be involved in the pathogenesis of acute promyelocytic leukaemia and viral infection. May play a role in chromatin-mediated regulation of gene expression although it does not bind to histone H3 tails.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Plasma Cell Myeloma.
In plain words · SP140 (Nuclear body protein SP140) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma and Mantle cell lymphoma.
SP140 (Nuclear body protein SP140) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma and Mantle cell lymphoma.
Component of the nuclear body, also known as nuclear domain 10, PML oncogenic domain, and KR body. May be involved in the pathogenesis of acute promyelocytic leukaemia and viral infection.
No product in this corpus aims at SP140 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA SP140: RNA group enriched (intestine 15 nTPM, lymphoid tissue 52 nTPM); high antibody staining in 2 normal tissues. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q13342; CIViC gene SP140; IntOGen SP140; Human Protein Atlas SP140 tissue; Open Targets ENSG00000079263 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Dent A.L. et al, Blood, 1996, "LYSP100-associated nuclear domains (LANDs): description of a new class of subnuclear structures and their relationship to PML nuclear bodies". Source.
Sources: HGNC HGNC:17133 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q13342 (protein name, function text, keywords and locations (REST API)); CIViC gene SP140 (1 evidence items, 0 assertions, 1 variants; diseases: Mantle Cell Lymphoma (GraphQL API, CC0)); IntOGen SP140 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Component of the nuclear body, also known as nuclear domain 10, PML oncogenic domain, and KR body. May be involved in the pathogenesis of acute promyelocytic leukaemia and viral infection. May play a role in chromatin-mediated regulation of gene expression although it does not bind to histone H3 tails. Location: Nucleus; Nucleus, PML body; Cytoplasm (UniProt). Locus 2q37.1 (HGNC).
RNA: group enriched (intestine 15 nTPM, lymphoid tissue 52 nTPM), detected in many normal tissues.
Medium: Appendix, Colon, Lung, Lymph node, Rectum, Small intestine, Spleen.
No cancer stained high; medium in lymphoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SP140" OR ABSTRACT:"SP140" OR TITLE:"SP140 nuclear body protein" OR ABSTRACT:"SP140 nuclear body protein" OR TITLE:"Nuclear body protein SP140" OR ABSTRACT:"Nuclear body protein SP140" OR TITLE:"LYSP100-B" OR ABSTRACT:"LYSP100-B" OR TITLE:"LYSP100-A" OR ABSTRACT:"LYSP100-A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SP140, not a curated reading list.